Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of eltrombopag when used to
increase and maintain platelet count. Platelet count to be maintained at a level sufficient
to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions,
and to avoid permanent discontinuation of antiviral therapy.